Advances in mobilization for the optimization of autologous stem cell transplantation
- 1 January 2009
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (9), 1412-1421
- https://doi.org/10.1080/10428190903096701
Abstract
In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to "mobilize" HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.Keywords
This publication has 92 references indexed in Scilit:
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood, 2009
- Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitroZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosisBlood, 2008
- Management strategies for poor peripheral blood stem cell mobilizationTransfusion and Apheresis Science, 2008
- Radioimmunotherapy-Based Conditioning Regimens for Stem Cell TransplantationSeminars in Hematology, 2008
- OX40 costimulation turns off Foxp3+ TregsBlood, 2007
- Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized by Granulocyte Colony Stimulating FactorTransplantation and Cellular Therapy, 2007
- Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100Blood, 2006
- Cytokines and hematopoietic stem cell mobilizationJournal of Cellular Biochemistry, 2006
- Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF)European Journal Of Cancer, 1993